Kivexa

Abacavir and lamivudine, the active ingredient in Kivexa, is a nucleoside reverse transcriptase inhibitor presented as a tablet for oral use. It treats HIV-1 infection in adults and adolescents. GNH USA supplies Kivexa as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kivexa, a nucleoside reverse transcriptase inhibitor, is indicated for the management of HIV-1 infection.

HIV-1 infection: reduces viral replication and improves immune function as part of combination antiretroviral therapy. Treatment‑naïve HIV-1 patients: provides a convenient dual‑drug regimen to simplify therapy. Switch therapy for stable patients: maintains viral suppression while reducing pill burden.

Kivexa may cause a range of adverse reactions. Monitoring and patient education are essential.

Common Side Effects: - Nausea - Headache - Fatigue - Diarrhea - Vomiting - Rash

Serious or Rare Side Effects: - Hypersensitivity reaction (including fever, rash, organ involvement) - Severe liver injury - Lactic acidosis or hepatic steatosis - Stevens‑Johnson syndrome/toxic epidermal necrolysis - Severe neutropenia or anemia - Cardiovascular events such as myocardial infarction

Before initiating Kivexa, several safety considerations should be addressed.

Assess renal function: adjust therapy if creatinine clearance is markedly reduced. Monitor hepatic enzymes: check liver function periodically during treatment. Screen for HLA‑B*5701: avoid abacavir in patients who test positive due to hypersensitivity risk. Counsel on adherence: consistent dosing is critical to prevent resistance. Avoid in known hypersensitivity: discontinue immediately if severe reaction occurs. Store at ambient temperature: keep in original packaging, protect from moisture and heat.

Kivexa can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Didanosine: increased risk of pancreatitis. - Ribavirin: heightened toxicity risk. - Other NRTIs with overlapping toxicity profiles.

Moderate Interactions (Monitor Closely): - Protease inhibitors (e.g., ritonavir): may raise lamivudine levels. - Non‑nucleoside reverse transcriptase inhibitors (e.g., efavirenz): can affect abacavir concentrations. - Warfarin: potential alteration of INR, requiring closer monitoring.